A strong hypothesis thus emerges: SGLT2 inhibition improves cardiac outcomes in individuals with type 2 diabetes by inducing metabolic shifts, reducing myocardial blood flow, and enhancing cardiac efficiency. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.